{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:23:34Z","timestamp":1789190614062,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T00:00:00Z","timestamp":1359504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00404-013-2722-2","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T16:18:09Z","timestamp":1359476289000},"page":"167-172","source":"Crossref","is-referenced-by-count":40,"title":["Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?"],"prefix":"10.1007","volume":"288","author":[{"given":"Amal Z.","family":"Azzam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa I.","family":"Hashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla A. F.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,30]]},"reference":[{"key":"2722_CR1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"R Moore","year":"2008","unstructured":"Moore R, Brown A, Miller M et al (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108:402\u2013408","journal-title":"Gynecol Oncol"},{"key":"2722_CR2","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","volume":"57","author":"J Escudero","year":"2011","unstructured":"Escudero J, Auge J, Filella X et al (2011) Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and non malignant diseases. Clin Chem 57:1534\u20131544","journal-title":"Clin Chem"},{"key":"2722_CR3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1586\/erm.10.87","volume":"10","author":"K Suh","year":"2010","unstructured":"Suh K, Park S, Castro A et al (2010) Ovarian cancer biomarkers for molecular biosensors and translation medicine. Expert Rev Mol Diag 10:1069\u20131083","journal-title":"Expert Rev Mol Diag"},{"issue":"5","key":"2722_CR4","first-page":"760","volume":"84","author":"P Hartge","year":"1994","unstructured":"Hartge P, Whittemore S, Itnyre J et al (1994) Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol 84(5):760\u2013764","journal-title":"Obstet Gynecol"},{"key":"2722_CR5","volume-title":"Robbins & Cotran Pathologic basis of diseases","author":"V Kumar","year":"2005","unstructured":"Kumar V, Fausto N, Abbas A (2005) Robbins & Cotran Pathologic basis of diseases, 7th edn. Saunders, Philadelphia","edition":"7"},{"key":"2722_CR6","volume-title":"Ovarian cancer: methods and protocols","author":"E Banks","year":"2000","unstructured":"Banks E (2000) The epidemiology of ovarian cancer. In: Bartlett JMS (ed) Ovarian cancer: methods and protocols. Humana Press, Totowa"},{"issue":"10","key":"2722_CR7","doi-asserted-by":"crossref","first-page":"200S","DOI":"10.1200\/JCO.2003.01.068","volume":"21","author":"RC Bast","year":"2003","unstructured":"Bast RC (2003) Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10):200S\u2013205S","journal-title":"J Clin Oncol"},{"key":"2722_CR8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E et al (2009) Cancer statistics 2009. CA Cancer J Clin 59:225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"2722_CR9","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"A Heitz","year":"2006","unstructured":"Heitz A, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. Int J Gynecol Obstet 95:S161\u2013S192","journal-title":"Int J Gynecol Obstet"},{"key":"2722_CR10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","volume":"100","author":"K Huhtinen","year":"2009","unstructured":"Huhtinen K, Suvitie P, Hissa J et al (2009) Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer 100:1315\u20131319","journal-title":"Br J Cancer"},{"key":"2722_CR11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","volume":"99","author":"D Rosen","year":"2005","unstructured":"Rosen D, Atkinson J, Yu Y et al (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267\u2013277","journal-title":"Gynecol Oncol"},{"key":"2722_CR12","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","volume":"54","author":"C Sturgeon","year":"2008","unstructured":"Sturgeon C, Duffy M, Stenman U et al (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem 54:e11\u2013e79","journal-title":"Clin Chem"},{"key":"2722_CR13","first-page":"558","volume":"61","author":"S How","year":"2006","unstructured":"How S, Liam C, Jamalludin A (2006) Serum cancer antigen 125 in patients with pleural effusions. Med J Malaysia 61:558\u2013563","journal-title":"Med J Malaysia"},{"key":"2722_CR14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","volume":"110","author":"L Havrilesky","year":"2008","unstructured":"Havrilesky L, Whitehead C, Rubatt J et al (2008) Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrences. Gynecol Oncol 110:374\u2013382","journal-title":"Gynecol Oncol"},{"key":"2722_CR15","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1177\/147323001103900507","volume":"39","author":"L Gao","year":"2011","unstructured":"Gao L, Cheng GHY, Dong L et al (2011) The role of HE4 in ovarian cancer: inhibiting tumor cell proliferation and metastasis. J Int Med Res 39:1645\u20131660","journal-title":"J Int Med Res"},{"key":"2722_CR16","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, Von-Horsten HH, Lin Y et al (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometroid ovarian carcinomas. Cancer Res 65:2162\u20132169","journal-title":"Cancer Res"},{"key":"2722_CR17","unstructured":"Chen L (ed) (2010) Diagnostic Gynecologic and Obstetric Pathology, 2nd edn. : People\u2019s Military Medical Press, Beijing, pp 268-394"},{"key":"2722_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s007950300002","volume":"36","author":"T Kaku","year":"2003","unstructured":"Kaku T, Ogawa S, Kawano Y et al (2003) Histological classification of ovarian cancer. Med Electron Microsc 36:9\u201317","journal-title":"Med Electron Microsc"},{"key":"2722_CR19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","volume":"70","author":"JL Benedet","year":"2000","unstructured":"Benedet JL, Bender H, Jones H et al (2000) FIGO staging classification and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynecol Obstet 70:209\u2013262","journal-title":"Int J Gynecol Obstet"},{"key":"2722_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1155\/2004\/241982","volume":"20","author":"K Terry","year":"2004","unstructured":"Terry K, Skates S, Mok S et al (2004) Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20:53\u201370","journal-title":"Dis Markers"},{"key":"2722_CR21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2217\/bmm.10.54","volume":"4","author":"S Dutta","year":"2010","unstructured":"Dutta S, Wang F, Fishman D (2010) The dire need to develop a clinically validated screening method for the detection of early stage ovarian cancer. Biomark Med 4:437\u2013439","journal-title":"Biomark Med"},{"issue":"5\u20136","key":"2722_CR22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2007\/309382","volume":"23","author":"D Badgwell","year":"2007","unstructured":"Badgwell D, Bast R (2007) Early detection of ovarian cancer. Dis Markers 23(5\u20136):397\u2013410","journal-title":"Dis Markers"},{"issue":"1","key":"2722_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","volume":"112","author":"R Moore","year":"2009","unstructured":"Moore R, Mc-Meekin D, Brown A et al (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40\u201346","journal-title":"Gynecol Oncol"},{"key":"2722_CR24","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/37.8.1379","volume":"37","author":"R Molina","year":"1991","unstructured":"Molina R, Filella X, Bruix J et al (1991) Cancer antigen 125 in serum and ascitic fluid for patients with liver disease. Clin Chem 37:1379\u20131383","journal-title":"Clin Chem"},{"key":"2722_CR25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","volume":"117","author":"B Nolen","year":"2010","unstructured":"Nolen B, Velikokhatnaya L, Marrangoni A et al (2010) Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117:440\u2013445","journal-title":"Gynecol Oncol"},{"key":"2722_CR26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","volume":"110","author":"R Moore","year":"2008","unstructured":"Moore R, Brown A, Miller M et al (2008) Utility of a novel serum tumor biomarker HE4 in patients with endometroid adenocarcinoma of the uterus. Gynecol Oncol 110:196\u2013201","journal-title":"Gynecol Oncol"},{"key":"2722_CR27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13277-010-0118-5","volume":"32","author":"S Yamashita","year":"2011","unstructured":"Yamashita S, Heagerty K, Hashimoto T et al (2011) Prognostic significance of HE4 in pulmonary adenocarcinoma. Tumor boil 32:265\u2013271","journal-title":"Tumor boil"},{"key":"2722_CR28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","volume":"23","author":"M Montagnana","year":"2009","unstructured":"Montagnana M, Lippi G, Ruzzenete O et al (2009) The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 23:331\u2013335","journal-title":"J Clin Lab Anal"},{"key":"2722_CR29","first-page":"3695","volume":"63","author":"I Hellstrom","year":"2003","unstructured":"Hellstrom I, Raycraft J, Hayden-ledbetter M et al (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63:3695\u20133760","journal-title":"Cancer Res"},{"key":"2722_CR30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-0-387-68969-2_2","volume":"622","author":"I Hellstrom","year":"2008","unstructured":"Hellstrom I, Hellstrom K (2008) SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and\/or each other. Adv Exp Med Biol 622:15\u201321","journal-title":"Adv Exp Med Biol"},{"key":"2722_CR31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/00016340701226138","volume":"86","author":"A Ayhan","year":"2007","unstructured":"Ayhan A, Guven S, Guven E et al (2007) Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 86:484\u2013490","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2722_CR32","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","volume":"276","author":"B Yin","year":"2001","unstructured":"Yin B, Lloyd K (2001) Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371\u201327375","journal-title":"J Biol Chem"},{"issue":"1","key":"2722_CR33","first-page":"111","volume":"11","author":"H Abdel-Azeez","year":"2010","unstructured":"Abdel-Azeez H, Labib H, Sharaf S et al (2010) HE4 and mesothelin: novel biomarker of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 11(1):111\u2013116","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-013-2722-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-013-2722-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-013-2722-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T10:03:46Z","timestamp":1595325826000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-013-2722-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,30]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2722"],"URL":"https:\/\/doi.org\/10.1007\/s00404-013-2722-2","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,30]]}}}